Treating Indolent Lymphoma: Common and Rare Types – Participant

• This course closed on 09/11/2024.

Credit Available: CME,NCPD,NP

• Enrollment in this course closed on 09/11/2024.

Activity Description

This webinar will focus on treating indolent lymphomas, including how to identify and diagnose indolent lymphoma subtypes, new and emerging treatment options, and the interprofessional healthcare team’s role in managing these patients. A review of resources you can provide to your patients, as well as additional education resources for you will also be provided.

Time to Complete Activity: 1.0 hour

This course is available from:

September 12, 2023 until September 11, 2024

Course Instructors

Jonas Paludo, MD Speaker

Assistant Professor of Medicine and Oncology, Mayo Clinic, Rochester, MN

Darci L. Zblewski, APRN, CNP Speaker

Department of Hematology-Lymphoma, Mayo Clinic, Rochester, MN

Target Audience

This activity is intended for hematologist/oncologists, oncology nurses, and other healthcare professionals involved in the care of patients with lymphoma.

Course content level for social workers: beginner and intermediate

Educational Objectives

After completing this activity, the participant should be better able to:

• • Identify indolent lymphoma subtypes and explain the importance of an accurate diagnosis
  • Explain new and emerging treatments for follicular lymphoma, marginal zone, and Waldenstrom macroglobulinemia (WM)
  • Identify the interprofessional healthcare team’s role in managing a patient with a chronic blood cancer 
  • Describe common treatment side effects and patient management
  • Review patient education and support resources

Accreditation, Support and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., and The Leukemia & Lymphoma Society.  Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Nurse Practitioner Continuing Education

This activity is approved for 1.00 contact hour(s) of continuing education (which includes 0.50 hour(s) of pharmacology) by the American Association of Nurse Practitioners®.
Activity ID# 23086272. This activity was planned in accordance with AANP Accreditation Standards and Policies.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (ONC, CBCN, CPHON, AOCNP), Oncology Nursing Practice (OCN), Professional Practice/Performance (BMTCN, AOCNP), Psychosocial Dimensions of Care (AOCNP, CPHON, ONC, CBCN), Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP), Treatment (OCN, CBCN, AOCNP, CPHON). 
Total points: 1.0*

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Support Statement

There is no commercial support associated with this CE activity.

Providers

This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc., in collaboration with the International Waldenstrom’s Macroglobulinemia Foundation.

Disclosure of Conflicts of Interest Policy

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Jonas Paludo, MD has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie- Lymphoma
Research Grant: Karyopharm- Lymphoma; Biofourmis- CAR T-Cell Therapy

Darci L. Zblewski, APRN, CNP, has nothing to disclose.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Planner
Lauren Berger, MPH
The Leukemia & Lymphoma Society

Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:

Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.

About this Activity

Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.